Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer’s Disease

INDIANAPOLIS, Aug. 22, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced they have received U.S. Food and Drug Administration (FDA) Fast Track designation for the development program in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving… http://www.prnewswire.com/news-releases/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293-an-investigational-treatment-for-early-alzheimers-disease-300315784.html